Kyverna Therapeutics has signed a research funding deal with Charité – Universitätsmedizin Berlin, in Germany, to study how therapies targeting immune B-cells may improve clinical outcomes of people with whole-body, or systemic, autoimmune diseases such as lupus. The deal also covers studies on CAR T-cell therapies, including Kyverna’s experimental…
Kyverna Therapeutics will use Verily Life Sciences’ high-resolution Immune Profiler to identify biomarkers to measure responses to KYV-101, Kyverna’s experimental cell therapy for lupus-related kidney disease. KYV-101 is being evaluated in an open-label trial, which is recruiting nine to 12 patients at clinical sites across the U.S.
Kyverna Therapeutics is planning to launch a Phase 1/2 trial in Germany to test KYV-101, its investigational cell therapy for lupus nephritis, a lupus complication characterized by kidney damage. The study was approved by the Paul Ehrlich Institute (PEI), which is responsible for examining clinical trials of investigational…
KYV-101, an investigational cell therapy from Kyverna Therapeutics, has been granted a fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of refractory lupus nephritis — a serious lupus complication characterized by kidney damage. Fast track status is granted to experimental therapies for…